Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) EPS (Basic) (2019 - 2024)

Historic EPS (Basic) for Bioadaptives (BDPT) over the last 6 years, with Q4 2024 value amounting to -$0.04.

  • Bioadaptives' EPS (Basic) fell 15041.96% to -$0.04 in Q4 2024 from the same period last year, while for Dec 2024 it was -$0.08, marking a year-over-year decrease of 2469.75%. This contributed to the annual value of -$0.08 for FY2024, which is 2876.39% down from last year.
  • Bioadaptives' EPS (Basic) amounted to -$0.04 in Q4 2024, which was down 15041.96% from -$0.0 recorded in Q3 2024.
  • In the past 5 years, Bioadaptives' EPS (Basic) ranged from a high of -$0.0 in Q3 2024 and a low of -$0.04 during Q4 2024
  • Its 5-year average for EPS (Basic) is -$0.01, with a median of -$0.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in Bioadaptives' EPS (Basic) was 9616.88% (2023), while the steepest drop was 143036.98% (2023).
  • Over the past 5 years, Bioadaptives' EPS (Basic) (Quarter) stood at -$0.01 in 2020, then fell by 12.62% to -$0.01 in 2021, then skyrocketed by 87.94% to -$0.0 in 2022, then tumbled by 1430.37% to -$0.02 in 2023, then tumbled by 150.42% to -$0.04 in 2024.
  • Its last three reported values are -$0.04 in Q4 2024, -$0.0 for Q3 2024, and -$0.0 during Q2 2024.